Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06728072 · ClinicalTrials.gov registry record · Phase 2
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
A Phase 2 study of Colorectal Cancer and CRC, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT06728072 is a Phase 2 study of Colorectal Cancer and CRC that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 97 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06728072, a Phase 2 study of Colorectal Cancer and CRC, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
Conditions Studied
Interventions
- DRUG Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2035-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06728072
The ClinicalTrials.gov registry entry for NCT06728072 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin is the first listed.
NCT06728072 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06728072 about?
NCT06728072 is a clinical study titled "Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer". This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
What is the current status of trial NCT06728072?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2025-03-07. Estimated completion is 2035-07-01.
What conditions does trial NCT06728072 study?
This clinical trial studies the following conditions: Colorectal Cancer, CRC.
What interventions are being tested in trial NCT06728072?
The interventions under investigation include: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin (DRUG).
Who is sponsoring clinical trial NCT06728072?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06728072 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.